Weight Loss & Wellness
Medically supervised therapy that supports weight management.
GLP-1 TherapyAOD-9604 PeptideB12 / MIC InjectionOptional: NAD+
IM nutrient injection · 503A compounded blend
B12 / MIC injection, cobalamin and lipotropic support under physician supervision.
B12/MIC is a combination intramuscular injection. Vitamin B12 (cobalamin) is an essential micronutrient with FDA-approved injectable forms for documented deficiency. MIC stands for methionine, inositol, and choline, three lipotropic compounds blended in a 503A compounded preparation. Together they are positioned for energy support and as an adjunct to fat-metabolism programs. We use it where clinical indication justifies it, not as a substitute for caloric balance, exercise, or evidence-based weight medication.
What it is
The B12/MIC injection delivers two clinically distinct components in a single intramuscular shot. Vitamin B12 is supplied as either cyanocobalamin (FDA-approved for B12 deficiency) or methylcobalamin (a 503A compounded form with theoretical CNS preference). MIC is a compounded blend of three lipotropic agents: methionine (a sulfur amino acid and SAM precursor), inositol (a phospholipid precursor with theoretical insulin-sensitizing effects), and choline (a phosphatidylcholine precursor central to lipid transport).
B12 has a long-established role in correcting documented deficiency, supporting hematopoiesis, methylation, and myelin maintenance. The MIC half is positioned as a lipotropic adjunct in metabolic and weight-management programs. We separate the evidence: strong for B12 in deficiency, moderate to limited for energy claims in B12-sufficient adults, and emerging or weak for MIC as an isolated weight-loss intervention.
We do not market B12/MIC as a standalone weight-loss treatment. MIC is not FDA-approved for fat loss, and rigorous randomized trials supporting that claim are lacking.
How it works
B12 cellular metabolism. Cobalamin is a cofactor for methionine synthase (which regenerates methionine from homocysteine and produces SAM, the universal methyl donor) and for methylmalonyl-CoA mutase (which feeds propionate into the citric acid cycle). Deficiency lowers SAM availability, raises homocysteine and methylmalonic acid, and impairs DNA synthesis, hematopoiesis, and myelin maintenance.
MIC lipotropic role. Choline and methionine support phosphatidylcholine synthesis, which is required to package triglycerides into VLDL particles for export from the liver. In choline-deficient states, hepatic fat accumulates. Inositol is a precursor for phosphoinositide signaling and has a theoretical role in insulin sensitivity. The clinical question is whether supplementing these substances in adults with adequate dietary intake produces meaningful body-composition change. The literature does not strongly support an isolated weight-loss effect.
Why intramuscular. Oral B12 absorption depends on intrinsic factor and is limited in pernicious anemia, atrophic gastritis, post-bariatric anatomy, and Crohn disease. IM injection bypasses these limitations and produces reliable serum levels. MIC components are also delivered IM for predictable bioavailability in the compounded preparation.
Stack context. B12/MIC is most useful as a nutrient-support adjunct inside a Weight Loss & Wellness stack alongside GLP-1 therapy or AOD-9604, or paired with NAD+ inside a longevity protocol. It is not a primary weight-loss therapy and is not a replacement for FDA-approved metabolic medications.
Conditions and use cases
Indications and status, by evidence grade.
- Documented B12 deficiency (low B12, elevated MMA or homocysteine, macrocytic anemia, neurologic signs). Strong evidence; on-label for cyanocobalamin.
- Vegetarian or vegan adults at risk of dietary B12 insufficiency. Strong rationale.
- Post-bariatric or malabsorption states (atrophic gastritis, Crohn disease, ileal resection). Strong rationale.
- Nutrient support adjunct during GLP-1 therapy. Reasonable adjunct where intake is reduced.
- General fatigue or low energy in B12-sufficient adults. Weak evidence; benefit not established by RCT.
- MIC as a standalone weight-loss therapy. Not supported by rigorous trial data; not FDA-approved for that indication.
Expected timeline
What patients commonly observe.
Week 0 to 2
Acute repletion
In documented deficiency, energy and cognitive symptoms often improve within 1 to 2 weeks. Hematologic markers begin to normalize.
Week 2 to 4
Normalization
Macrocytic indices and homocysteine continue to fall. Neurologic symptoms (paresthesia, ataxia) improve more slowly and recovery may be incomplete in long-standing deficiency.
Month 1 to 3
Steady-state stack use
Weekly or biweekly maintenance is typical when used inside a Weight Loss & Wellness stack or alongside hormone therapy. MIC component reassessed against body-composition goals.
Month 3 to 6
Maintenance and reassessment
Provider reassesses cadence based on clinical response. Long-term frequency individualized to clinical indication.
Stacks that include this therapy
B12 / MIC injection appears in this stack.
Investment and access
Care plans, not menus.
Genesis Longevity therapies are dispensed only after a complimentary consultation and Good Faith Exam. Schedule yours to receive a personalized plan tailored to your biology and goals.
Side effects
What patients commonly report.
Common. Injection-site discomfort, mild erythema, transient warm flush. Some patients report a brief energy or alertness sensation in the first day after injection.
Less common. Niacin-style flushing has been reported with inositol-containing blends in some patients. GI upset or nausea. Mild headache.
Rare but relevant. Allergic or hypersensitivity reaction. Acute hypokalemia during the first week of B12 repletion in severe macrocytic anemia, monitored by the provider. Polycythemia with rebound erythropoiesis in profound deficiency. The MIC blend is not characterized in randomized trials, so its long-term adverse profile is less well defined than B12 alone.
Contraindications
Who should not use this therapy.
Show contraindications
Absolute. Leber hereditary optic neuropathy (high-dose cobalamin can worsen disease). Known cobalt or component hypersensitivity. Active untreated polycythemia vera.
Relative. Pregnancy and lactation (standard B12 doses are generally safe; MIC has limited safety data and is typically avoided). Severe renal impairment. Severe hepatic disease, where compounded blends warrant caution. Concurrent severe macrocytic anemia requires supervised initiation due to hypokalemia risk.
Pairs well with
Therapies that complement this protocol.
- FDA-approved
GLP-1 Therapy
Appetite regulation and clinically guided metabolic weight loss.
Strong evidence - 503A compounded
AOD-9604
Targeted stubborn fat mobilization with no appetite or blood sugar effect.
Weak evidence - 503A compounded
Glutathione Injection
Antioxidant and detoxification support.
Moderate evidence
Frequently asked
Frequently asked questions about B12 / MIC injection.
Two parts. Vitamin B12 (cyanocobalamin or methylcobalamin) and MIC, a compounded blend of methionine, inositol, and choline. B12 supports methylation, hematopoiesis, and myelin maintenance. MIC components are positioned as lipotropic support, meaning they participate in lipid transport pathways. The combination is delivered as a single intramuscular injection.
It is commonly used alongside GLP-1 therapy as a nutrient-support adjunct, especially when food intake drops and protein and micronutrient intake become limited. There is no known direct interaction. Your provider will assess B12 status and decide cadence rather than dosing reflexively.
Not as a standalone treatment. Rigorous randomized trial evidence does not support MIC injections as an isolated fat-loss therapy. Sustainable weight change requires caloric balance, resistance training, and where appropriate FDA-approved metabolic medication. We position B12/MIC as a supportive adjunct, not a replacement, and we do not market it as a weight-loss shot.
Typical protocols are weekly during an initial loading phase (often 4 to 8 weeks), then transitioning to biweekly or monthly maintenance based on clinical response. In confirmed B12 deficiency, providers follow standard repletion schedules. Cadence is individualized.
Cyanocobalamin is FDA-approved, well-studied, and converted in the body to active forms. Methylcobalamin is a 503A compounded active form with theoretical CNS preference. Head-to-head clinical outcome data are limited. Either can be appropriate; we choose based on indication and provider judgment.
Sources
Citations & references
Status & disclosures
- FDA status: B12 approved · MIC compounded only
- Injectable cyanocobalamin is FDA-approved for vitamin B12 deficiency. The MIC blend (methionine, inositol, choline) is not FDA-approved as a drug or for weight-loss claims and is prepared as a 503A compounded preparation.
- 503A compounded combination
- B12/MIC combination injections are compounded by licensed 503A pharmacies under U.S. FDA regulations. Genesis sources from regulated compounders that follow USP standards.
- Not marketed as a weight-loss shot
- We do not position B12/MIC as a fat-loss treatment. It is offered as a nutrient and methylation-support adjunct, with use governed by clinical indication.
Next step
Talk to a Genesis provider about B12 / MIC injection.
Schedule a consultation. Physician-led, evidence-graded.
Or keep reading: See the Weight Loss & Wellness stack